My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

22.19 -0.63 (-2.76%)

Streaming Delayed Price Updated: 9:47 AM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS

September 29, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle ↗

September 29, 2022

The drug has faced two advisory committees and a delayed review date.

Via Investor's Business Daily

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗

September 29, 2022

Patients didn't show any improvements in a study meant to test multiple drugs.

Via Investor's Business Daily

Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries

September 14, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

4 Analysts Have This to Say About Amylyx Pharma ↗

September 08, 2022

Analysts have provided the following ratings for Amylyx Pharma (NASDAQ:AMLX) within the last quarter:

Via Benzinga

After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful ↗

September 08, 2022

Via Benzinga

Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today? ↗

September 08, 2022

Amylyx Pharmaceuticals (AMLX) stock is rocketing higher on Thursday following an update from the FDA on its ALS treatment.

Via InvestorPlace

Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds

September 12, 2022

From Amylyx Pharmaceuticals

Via Business Wire

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗

September 09, 2022

Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.

Via Investor's Business Daily

US Stocks Flat, Crude Oil Rises 2% ↗

September 08, 2022

U.S. stocks traded almost flat in volatile trading on Thursday following the release of jobless claims data.

Via Benzinga

US Stocks Turn Higher, Nasdaq Jumps 100 Points ↗

September 08, 2022

U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday.

Via Benzinga

FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate ↗

September 06, 2022

Via Benzinga

The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff ↗

September 02, 2022

The FDA's advisors will meet Wednesday to discuss the experimental ALS treatment.

Via Investor's Business Daily

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday ↗

September 08, 2022

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

September 08, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Via Benzinga

AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022 ↗

September 08, 2022

Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details!

Via InvestorPlace

Dow Drops 100 Points; US Jobless Claims Fall Further Last Week ↗

September 08, 2022

U.S. stocks traded mostly lower this morning, with the Dow Jones dropping 100 points on Thursday.

Via Benzinga

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS

September 07, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Stock Trading Halted Today

September 07, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035

September 02, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday ↗

September 06, 2022

Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 11, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029

August 11, 2022

Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...

Via FinancialNewsMedia

Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022

August 03, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases

July 18, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases

July 06, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.